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Abstract: Probiotics and synbiotics are used to treat chronic diseases, principally due to their role in
immune system modulation and the anti-inflammatory response. The present study reviewed
the effects of probiotics and synbiotics on intestinal chronic diseases in in vitro, animal, and
human studies, particularly in randomized clinical trials. The selected probiotics exhibit in vitro
anti-inflammatory properties. Probiotic strains and cell-free supernatants reduced the expression of
pro-inflammatory cytokines via action that is principally mediated by toll-like receptors. Probiotic
administration improved the clinical symptoms, histological alterations, and mucus production in
most of the evaluated animal studies, but some results suggest that caution should be taken when
administering these agents in the relapse stages of IBD. In addition, no effects on chronic enteropathies
were reported. Probiotic supplementation appears to be potentially well tolerated, effective, and
safe in patients with IBD, in both CD and UC. Indeed, probiotics such as Bifidobacterium longum 536
improved the clinical symptoms in patients with mild to moderate active UC. Although it has been
proposed that probiotics can provide benefits in certain conditions, the risks and benefits should
be carefully assessed before initiating any therapy in patients with IBD. For this reason, further
studies are required to understand the precise mechanism by which probiotics and synbiotics affect
these diseases.
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1. Introduction
In 1907, the Russian Ilya Ilyich Mechnikov suggested that microbial ingestion improved host
health. Indeed, he hypothesized that the consumption of lactic-acid-producing bacteria (LAB) strains
found in yogurt might enhance longevity [1].
LAB is a heterogeneous group of microorganisms that are often present in a person’s gut,
introduced through the ingestion of fermented foods, as well as in the gastrointestinal and urogenital
tract of animals. Some of these strains have probiotic effects [2]. In particular, strains belonging to
Bifidobacterium, Enterococcus, and Lactobacillus are the most widely used probiotic bacteria [3–5].
Werner Kollath was probably the first person to use the word "probiotic” in 1953 [6]. In current
use, the term refers to microorganisms that confer a health benefit to the host when administered in
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adequate amounts [7,8]. In addition, dead bacteria and bacterial molecular components may exhibit
probiotic properties [9]. In 2014, the International Scientific Association for Probiotics and Prebiotics
stated that the development of metabolic by-products, dead microorganisms, or other microbial-based,
nonviable products has potential; however, these do not fall under the probiotic construct [10].
When ingested, probiotics produce microbial transformation in the intestinal microbiota and
exert several health-promoting properties, including maintenance of the gut barrier function and
modulation of the host immune system [11–16].
By contrast, a prebiotic is a non-viable food component that confers a health benefit on the host
that is associated with the modulation of the intestinal microbiota. Prebiotics may be a fiber, but a fiber
is not necessarily a prebiotic. Using prebiotics and probiotics in combination is often described as
synbiotics, but only if the net health benefit is synergistic [17,18].
Hence, probiotics and synbiotics are consumed in numerous and diverse forms, such as yogurt
and fermented milks, cheese, and other fermented foods. The use of probiotics and synbiotics in
preventive medicine to maintain a healthy intestinal function is well documented. In addition, both
probiotics and synbiotics have been proposed as therapeutic agents for gastrointestinal disorders and
other pathologies [19,20].
Intestinal diseases, particularly infectious illnesses, were first recognized as a major health issue
in developing countries. However, intestinal chronic diseases are more prevalent in developed
regions, and their incidence has continued to increase over the past several decades in various regions
worldwide [21]. The exact pathogenic mechanism of the onset of selected intestinal chronic diseases
remains mostly unexplained [22]. The principal clinical manifestations of intestinal chronic diseases are
inflammatory bowel diseases (IBDs), necrotizing enterocolitis (NEC), and malabsorption syndromes.
IBD is a term used to describe four pathologies: ulcerative colitis (UC), Crohn’s disease (CD),
pouchitis, and microscopic colitis. These conditions are systemic disorders that affect the gastrointestinal
tract and have frequent extraintestinal manifestations [23,24], in which the epithelial barrier function
is a critical factor for onset. In addition, native immunity and commensal enteric bacteria play
a role [25,26].
The current treatment of IBD first involves the induction of remission, which is followed
by maintaining remission. Patients with an active disease are treated with topical or systemic
5-aminosalicylic acids (5-ASA), corticosteroids, or immunomodulators, such as azathioprine and
6-mercaptopurine, in addition to anti-TNF monoclonal antibodies [27,28].
Data from clinical trials indicate that certain intestinal disease conditions, including NEC,
pouchitis, UC, and irritable bowel syndrome (IBS), have yielded clinical benefits with some probiotic
and synbiotic interventions [29], because probiotics largely act directly or indirectly on the intestinal
microbiota [30].
Several experimental methods are available to assess the effect of probiotics or synbiotics on
intestinal diseases, especially their anti-inflammatory properties. Both in vitro and in vivo studies
have been conducted. In vitro studies principally involve intestinal porcine epithelial cells (IPEC) J2,
CaCo-2 cells, human dendritic cells (DC) obtained from peripheral blood and umbilical cord blood,
monocyte-derived DCs, peripheral blood mononuclear cells, and intestinal T cells [31–33]. In vivo
studies involve animal models (mice, rats, and dogs) with chemical inflammation induction or human
patients. Despite this variety of studies, however, the mechanisms underlying the beneficial effects of
probiotics or synbiotics remain incompletely understood.
Therefore, the present review was conducted to investigate the anti-inflammatory effects of
probiotics and synbiotics on chronic intestinal diseases in in vitro and in vivo studies, as well as
current evidence from human randomized clinical trials (RCTs).
2. Materials and Methods
A comprehensive search of the relevant literature was performed using electronic databases,
including MEDLINE (PubMed), EMBASE, and the Cochrane Library. MEDLINE through PubMed
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was searched for scientific articles that were published between 2010 and 2017 in English using the
MeSH terms “probiotics” and “synbiotics”, combined with “intestinal diseases,” “Crohn’s disease,”
and “ulcerative colitis”. We evaluated the results obtained using the following equation search:
(“intestinal diseases”(All Fields) OR “Crohn’s disease”(All Fields) OR “colitis, Ulcerative”(All Fields))
and (“probiotics”(All Fields) OR “synbiotics”(All Fields)). Our search yielded 326 articles. A total
of 38 articles were selected. Additionally, we searched the reference lists of the included articles for
potential relevant literature.
3. Results
3.1. In Vitro Studies
Substantial evidence from in vitro studies suggests that known and potential probiotics exhibit
strain-specific anti-inflammatory effects. A large inventory of animal and human cell lines is available
as models of the gut [3], including DCs, porcine intestinal epitheliocyte (PIE) cells, intestinal epithelial
cells (IEC)-6, HT-29, and IPEC-J2. In most of the in vitro experimental models, epithelial cells were
cultivated as monolayers in which the establishment of a functional epithelial feature was not achieved.
DCs generate primary T-cell responses and mediate intestinal immune tolerance to prevent overt
inflammation in response to gut microbiota. Indeed, DCs play a key role in UC pathogenesis [32,33].
Lactobacillus casei Shirota (LcS) was tested on human DCs from healthy controls and active UC patient
samples. DCs from UC patients exhibit a reduced stimulatory capacity for the T-cell response and an
enhanced expression of skin-homing markers, such as cutaneous lymphocyte-associated antigen (CLA)
and C-C motif chemokine receptor 4 (CCR4) on stimulated T-cells. Those responses were characterized
by increased interleukin (IL)-4 production and a loss of IL-22 and interferon (IFN)-γ secretion. LcS
treatment restored the normal stimulatory capacity via a reduction in Toll-like receptor (TLR)-2 and
TLR4 expression [32,33].
TLRs are transmembrane proteins expressed on various immune and non-immune cells, such as
B-cells, natural killer cells, DCs, macrophages, fibroblast cells, epithelial cells, and endothelial cells.
They are members of a family of evolutionarily conserved pattern recognition receptors that identify
a wide range of microbial components [34].
Lactobacillus plantarum strain CGMCC1258 has a dual effect in an IPEC-J2 model that involves epithelial
permeability, the expression of inflammatory cytokines, and an abundance of tight junction proteins. In this
model, the damage was induced by enterotoxigenic Escherichia coli K88. The aforementioned probiotic
strain decreased the transcript levels of IL-8, tumor necrosis factor (TNF-α), and negative regulators
of TLRs, such as the single Ig Il-1-related receptor (SIGIRR), B-cell CLL/lymphoma 3 (Bcl3), and
mitogen-activated protein kinase phosphatase-1 (MKP-1). Moreover, L. plantarum treatment reduced
the gene and protein expression of occludin [35]. These results indicated that L. plantarum reduced the
expression of pro-inflammatory cytokines induced by E. coli K88, possibly by modulating the TLR,
nuclear factor kappa-B (NF-κB), and mitogen-activated protein kinase (MAPK) pathways [35].
The anti-inflammatory effects of Lactobacillus delbrueckii subsp. delbrueckii TUA4408L and its
extracellular polysaccharide against E. coli 987P were evaluated in PIE cells. The activation of the
MAPK and NF-κB pathways induced by E. coli 987P was downregulated via the upregulation of TLR
negative regulators. In fact, TLR2 had a principal role in the immunomodulatory action of the probiotic
strain [36].
Cell-free supernatants (CFS) from E. coli Nissle 1917 and Lactobacillus rhamnosus GG were
evaluated for their capacity to prevent 5-fluorouracil-induced damage to IEC-6. Pre-treatment with the
supernatants of those strains prevents or inhibits enterocyte apoptosis and the loss of the intestinal
barrier function induced by 5-fluorouracil, potentially forming the basis of a preventative treatment
modality for mucositis [37].
Finally, our investigation group assessed in vitro studies related to probiotics and their
anti-inflammatory effects. Indeed, selected probiotics have been shown to modulate immune
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responses and inflammatory biomarkers in human DCs generated from CD34+ progenitor cells
(hematopoietic stem cells) harvested from umbilical cord blood. The DCs exhibited surface antigens
of dendritic Langerhans cells similar to the lamina propria DCs in the gut [38–40]. We co-incubated
these intestinal-like human DCs with Bifidobacterium breve CNCM I-4035 or its CFS, Salmonella typhi
CECT 725, or a combination of these treatments for 4 h. These treatments up-regulated TLR-9 gene
transcription. In addition, CFS was a more powerful inducer of TLR-9 expression compared with
probiotic bacteria in the presence of S. typhi. Both treatments induced Toll-interacting protein (TOLLIP)
gene expression. Furthermore, CFS decreased the pro-inflammatory cytokines and chemokines in DCs
that were challenged with S. typhi. By contrast, B. breve CNCM I-4035 was a potent inducer of the
pro-inflammatory cytokines TNF-α, IL-8, and RANTES (regulated upon the activation of normal T cells,
expressed, and presumably secreted), and anti-inflammatory cytokines, including IL-10. CFS restored
the transforming growth factor (TGF)-β levels in the presence of S. typhi. These results indicate
that B. breve CNCM I-4035 affects the intestinal immune response, whereas its supernatant exerts
anti-inflammatory effects that are mediated by DCs. Similarly, Lactobacillus paracasei CNCM I-4034 and
its CFS decreased pro-inflammatory cytokines and chemokines in human intestinal DCs that were
challenged with S. typhi CECT 725. CFS was as effective as bacteria in reducing pro-inflammatory
cytokine expression. These treatments strongly induced the transcription of the TLR-9 gene. In addition,
an upregulation of the CASP8 and TOLLIP genes was observed. L. paracasei CNCM I-4034 was a potent
inducer of TGF-β2 secretion, whereas the supernatant enhanced the innate immunity through the
activation of TLR signaling. Moreover, L. rhamnosus CNCM I-4036 and its CFS were challenged
with E. coli CECT 742, CECT 515, and CECT 729. L. rhamnosus treatment induced the production of
TGF-β1 and TGF-β2, whereas the CFS increased TGF-β1 secretion. The two treatments induced the
gene transcription of TLR-9. L. rhamnosus activated TLR-2 and TLR-4 gene expression, whereas CFS
increased TLR-1 and TLR-5 gene expression [38–40].
Other selected probiotics exhibit in vitro anti-inflammatory properties. Both probiotic strains and
CFS reduced the expression of pro-inflammatory cytokines via an action principally mediated by TLRs.
Table 1 summarizes the principal investigations of probiotic effects in in vitro studies.
Table 1. Summary of probiotic anti-inflammatory effects in In Vitro studies.
Reference Cell Type Probiotic Strain Type of Study Main Outcome
Mann et al. 2014,
2013 [32,33] human DC L. casei Shirota In vitro
DC from UC patients samples have an increase
of IL-4 production and loss of IL-22 and IFN-γ
secretion. L. casei Shirota treatment restored the
normal stimulatory capacity through a reduction
in the TLR-2 and TLR4 expression
Wu et al., 2016 [35] IPEC-J2model
L. plantarum strain
CGMCC1258 In vitro
L. plantarum decreased transcript abundances of
IL-8, TNF-α, and negative regulators of TLRs.
Moreover, L. plantarum treatment decreased the
gene and protein expression of occludin
Wachi et al., 2014 [36] PIE cells L. delbrueckii subsp.delbrueckii TUA4408L In vitro
The activation of MAPK and NF-κB pathways
induced by E. coli 987P were downregulated




E. coli Nissle 1917 and
L. rhamnosus GG In vitro
Pre-treatment with these probiotics could
prevent or inhibit enterocyte apoptosis and loss





L. paracasei CNCM I-4034,
B. breve CNCM I-4035, and
L. rhamnosus CNCM I-4036
In vitro
Induction of TLR-9 expression and TGF-β2
secretion. CFS treatment decreased the
pro-inflammatory cytokines and chemokines
CFS, cell-free supernatant; DC, dendritic cells; FU, fluorouracil; IEC, intestinal epithelial cells; IL, interleukin;
IFN, interferon; IPEC, intestinal porcine epithelial cells, MAPK, mitogen-activated protein kinase; NF-κB, nuclear
factor κ-B; TGF, transforming growth factor; TNF-α, tumor factor necrosis alpha; TLR, toll-like receptor; UC,
ulcerative colitis.
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3.2. In Vivo Studies
3.2.1. Animals
The anti-inflammatory effects of probiotics have been demonstrated in experimental models.
Probiotic supplementation provides protective effects during spontaneous and chemically induced
colitis by downregulating the production of inflammatory cytokines or by inducing regulatory
mechanisms in a strain-specific manner [3].
Dextran Sulfate Sodium
The anti-inflammatory effects of Lactobacillus acidophilus, L. plantarum, Bifidobacterium lactis, B. breve,
and inulin on UC colitis have been investigated. Acute UC was induced in Swiss mice using dextran
sulfate sodium (DSS). The production of nitric oxide (NO) was evaluated in the supernatants of
peritoneal macrophage cultures. The oral administration of probiotic strains and inulin reduced
the severity of DSS-induced colitis. These treatments lead to a reduction in NO levels in peritoneal
macrophage cultures [41]. The same mixture of strains was tested in another DSS-induced colitis
animal model for seven days. Probiotic administration improved clinical symptoms and histological
alterations observed in the colitis group, reduced NO production by peritoneal macrophages in
DSS-treated mice, and enhanced mucus production in both DSS-treated and healthy mice [42].
Lactobacillus reuteri BR11 reduces the severity of experimental IBD, principally via a mechanism of
thiol production [43]. Male Sprague–Dawley rats were administered 2% DSS to induce colitis. L. reuteri
BR11 or L. reuteri BR11 mutants deficient in the cystine-uptake system were administered for 12 days.
DSS administration resulted in significant colonic deterioration, including a reduced crypt area and
increased damage severity. Probiotic administration partially alleviated the DSS effects, with a minor
improvement in the crypt area. The administration of the mutant strain to colitic animals failed to
produce significant differences when compared with the DSS control [43].
Lactobacillus fermentum CCTCC M206110, Lactobacillus crispatus CCTCC M206119, and L. plantarum
NCIMB8826 were selected to assess the therapeutic effects on experimental colitis in BALB/c mice
treated with DSS. L. fermentum CCTCC M206110 treatment resulted in reduced weight loss, colon
length shortening, disease activity index scores, and histologic scores, whereas the L. crispatus CCTCC
M206119 treatment group exhibited greater weight loss and colon length shortening, histologic scores,
and more severe inflammatory infiltration. L. plantarum NCIMB8826 treatment improved the weight
loss and colon length shortening, with no significant influence on the disease activity index and
histologic damage in the colitis model [44]. The administration of an L. crispatus CCTCC M206119
supplement aggravated DSS-induced colitis, whereas L. fermentum CCTCC M206110 effectively
attenuated DSS-induced colitis. The potential probiotic effect of L. plantarum NCIMB8826 on UC
has not been assessed to date [44].
A previous study demonstrated that the intrarectal administration of mouse cathelin-related
antimicrobial peptide (mCRAMP) alleviates DSS-induced colitis by preserving the mucus layer
and reducing pro-inflammatory cytokines production [45]. A mutant of Lactococcus lactis NZ3900
that produces mCRAMP was tested in a murine model of DSS-induced colitis for seven days.
Compared with the control group with colitis, cathelicidin-transformed L. lactis improved the clinical
symptoms, maintained crypt integrity, and preserved the mucus content. The number of apoptotic
cells, myeloperoxidase (MPO) activity, and malondialdehyde level were also significantly reduced.
The increases in fecal microbiota in colitis animals were markedly prevented [45].
Hong et al., 2010 evaluated a mixture of Lactobacillus brevis HY7401, Lactobacillus sp. HY7801, and
Bifidobacterium longum HY8004 in an acute DSS-induced colitis model for seven days [46]. Increased
levels of acetate, butyrate, and glutamine, in addition to decreased levels of trimethylamine, were
noted in the feces of the probiotic group compared with the DSS-alone-treated mice. The increased
short chain fatty acid levels in the feces of mice fed the mixture indicates that probiotics have protective
effects against DSS-induced colitis via modulation of the gut microbiota [46].
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E. coli Nissle, 1917 was tested in a mouse model of reactivated colitis. Colitis was induced by
adding DSS for five days. Two weeks later, colitis was reactivated by subsequent exposure to DSS.
E. coli Nissle, 1917 administration exerted intestinal anti-inflammatory effects and attenuated colitis
reactivation, as shown by reduced disease activity index values. Moreover, probiotic administration
decreased the expression of pro-inflammatory cytokines and increased intestinal mucin-like and zona
occludens-1 expression [47].
On the other hand, the effects of L. rhamnosus NutRes 1 and B. breve NutRes 204 on a DSS-induced
chronic murine colitis model were assessed. Chronic colitis was induced by two DSS treatment cycles
with a 10-day rest period. The probiotic supplementation was started after the first DSS treatment
cycle and continued until the end of the experiment. L. rhamnosus NutRes 1, but not B. breve NutRes
204, rapidly and effectively improved the DSS-induced bloody diarrhea during the resolution phase.
However, an increased expression of TLR2, TLR6, chemokine (C-C motif) ligand 2, IL-1β, TNF-α, and
IL-6 was found in DSS-treated mice with L. rhamnosus supplementation. These results suggest caution
in the use of probiotics in the relapse stages of IBD [48].
Capsules with bifidobacteria, lactobacilli, and Streptococcus thermophilus DSM24731 were
administered to mice exposed to 5, 10, and 15 cycles of DSS. A probiotic mixture attenuated the
disease activity index score and colon inflammation after 5, 10, and 15 cycles of DSS and reduced the
histological alterations and the incidence of colonic dysplastic lesions in the three periods studied.
In addition, the probiotic reduced the proliferating cell nuclear antigen labeling index and TNF-α, IL-1β,
IL-6 production, and cyclooxygenase (COX)-2 expression, and increased IL-10 levels in colon tissue
in the three periods assayed [49]. Additionally, in rats treated with DSS for seven days, the probiotic
mixture exhibited anti-inflammatory properties, including reducing the disease activity index, MPO
activity, iNOS, COX-2, NF-κB, TNF-α, IL-6, and p-Akt expression, and increasing IL-10 expression in
colonic tissue. In addition, probiotic administration decreased TNF-α and IL-6, and increased IL-10 serum
levels [50]. Moreover, probiotic administration was evaluated in acute intestinal ischemia/reperfusion
injury in adult 129/SvEv mice. The mixture of strains reduced local tissue inflammation and injury.
The reduction in local inflammation after a two-week course of the mixture was correlated with
a significant reduction in active IL-1β levels and tissue levels of MPO. Active NF-κB levels were
significantly higher in the control group, consistent with the tissue inflammation. Inflammation was
attenuated by probiotic administration. Finally, the administration of bifidobacteria, lactobacilli, and
S. thermophilus did not cause any systemic inflammation or lung injury [51].
Bacillus subtilis R179 also exhibits a protective effect in IBD. The effects of B. subtilis were analyzed
using a mouse DSS model of colitis in which a higher dose ameliorated gut inflammation and
dysbiosis [52].
2,4,6-Trinitrobenzenesulfonic Acid
The impact of L. plantarum 21 on inflammatory mediators in 2,4,6-trinitrobenzenesulfonic acid
(TNBS)-induced colitis in rats has been evaluated. Treatment with L. plantarum 21 for 14 days
after the induction of colitis decreased thiobarbituric acid reactive substances (TBARS) and NO,
and increased glutathione concentrations. The IL-1β and TNF-α proteins, in addition to mRNA
expression, were down-regulated, whereas IL-10 protein and mRNA expression was up-regulated in
L. plantarum 21-treated rats. In addition, probiotic treatment attenuated macroscopic colonic damage
and histopathological changes produced by TNBS [53].
The effects of lactobacilli and bifidobacteria administration on TNF-α and TLR4 expression in
a rat colitis model induced by TNBS were also investigated. No significant differences were found in
TLR4 and TNF-α expression between the two-week probiotics treatment group and the colitis group,
whereas significant reductions were found in rats treated with probiotics for four weeks compared
with the TNBS group [54].
The effects of Butyricicoccus pullicaecorum CCUG 55,265 in a rat colitis model with TNBS and
a Caco-2 cell model were analyzed. B. pullicaecorum administration resulted in a significant protective
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effect based on macroscopic and histological criteria and decreased intestinal MPO, TNF-α, and IL-12
levels. B. pullicaecorum supernatant prevented the increase in IL-8 secretion induced by TNF-α and
IFN-γ in a Caco-2 cell model [55].
Other Intestinal Inflammation Models
Chronic enteropathies (CE) are believed to be caused by an aberrant immune response towards
the intestinal microbiome. The in vitro effects of the probiotic Enterococcus faecium NCIMB 10,415 E1707
were previously evaluated using canine cells (e.g., whole blood, intestinal biopsies), but data on in vivo
efficacy are lacking. Dogs diagnosed with CE were prospectively recruited to receive a hydrolyzed
elimination diet, in addition to either a synbiotic product containing E. faecium NCIMB 10,415 E1707
or a placebo for six weeks. Both veterinary staff and owners were blinded to the treatment. Of the
45 cases recruited, 12 completed the clinical trial. Seven dogs received the symbiotic and five received
the placebo product. No difference was noted between groups or treatments regarding the clinical
efficacy and histology scores [56]. Casp-1 and NLRP3 gene expression was reduced in the CE samples
when compared with the controls. Ex vivo treatment with E. faecium NCIMB 10,415 E1707 reduced
NLRP3 expression in the control samples [57].
The effects of L. delbrueckii subsp. bulgaricus in an intestinal malfunction mouse model induced by
lincomycin hydrochloride were tested. Consequently, L. delbrueckii administration increased secretory
immunoglobulin A and decreased intestinal pathological damage [58].
L. plantarum LS/07 CCM7766 alone or in combination with inulin was assessed in rats with chronic
inflammation. N,N-dimethylhydrazine administration triggered the production of IL-2, IL-6, IL-17, and
TNF-α, as well as the expression of NF-κB, COX-2, and iNOS, and caused the depletion of goblet cells.
L. plantarum LS/07 CCM7766 alone and in combination with inulin abolished the inflammatory process
in the jejunal mucosa by inhibiting the production of pro-inflammatory cytokines and stimulating
IL-10 cytokine synthesis, whereas the TGF-β1 levels did not change significantly [59].
Ogita et al., 2015 tested the effects of L. rhamnosus OLL2838, Bifidobacterium infantis ATCC 15,697,
and S. thermophilus Sfi 39 on the maturation of bone marrow-derived DCs from mice [60]. L. rhamnosus
OLL2838 induced appreciable levels of IL-10 and NO production, whereas S. thermophilus Sfi 39
essentially elicited IL-12 and TNF-α [60]. In addition, L. rhamnosus OLL2838 was evaluated in an
in vivo model of gluten-specific enteropathy characterized by villus blunting, crypt hyperplasia,
high levels of intestinal IFN-γ, increased cell apoptosisin lamina propria, and reduced intestinal
glutathione S-transferase activity. Probiotic administration enhanced the total glutathione and
glutathione S-transferase activity, whereas caspase-3 activity was reduced. However, the probiotic
strain failed to recover the normal histology and further increased intestinal IFN-γ [60].
Finally, Wu et al. identified a novel role of probiotics in activating vitamin D receptor (VDR), thus
inhibiting inflammation, using cell models and VDR knockout mice [61]. The probiotics L. rhamnosus
GG ATCC 53,103 and L. plantarum increased VDR protein expression in both mouse and human
intestinal epithelial cells. Moreover, the role of probiotics in regulating VDR signaling was assessed
in vivo using a Salmonella typhimurium ATCC 14,028-induced colitis model in VDR knockout mice.
Probiotic treatment conferred physiological and histologic protection from colitis in mice, whereas
probiotics did not affect the knockout mice. Probiotic treatment also enhanced the number of Paneth
cells, which secrete AMPs for host defense [61].
Animal studies seem to be more extensively used than cell models in the evaluation of probiotic
properties. Probiotic administration might improve clinical symptoms, histological alterations, and
mucus production in the majority of the evaluated studies, but some results suggest that caution
should be taken when administering these agents in the relapse stages of IBD. In addition, no effects
on chronic enteropathies were noted. Table 2 shows the main investigations regarding the probiotic
anti-inflammatory effects in animal studies.
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Table 2. Summary of probiotic anti-inflammatory effects in animal studies.





2012 [41] Swiss mice
L. acidophilus, L. plantarum,
B. lactis, B. breve, and inulin In vivo, DSS-induced colitis
Oral administration of probiotic strains and inulin
decreased severity colitis -
Toumi et al.,
2013 [42] Swiss mice
L. acidophilus, L. plantarum,
B. lactis, B. breve In vivo, DSS-induced colitis
Probiotic administration improved clinical symptoms,




rats L. reuteri BR11 In vivo, DSS-induced colitis
Probiotic administration partially alleviated the DSS
effects, with a minor improvement in crypt area -
Cui et al., 2016 [44] BALB/c mice
L. fermentum CCTCC M206110,
L. crispatus CCTCC M206119, and
L. plantarum NCIMB8826
In vivo, DSS-induced colitis
L. fermentum CCTCC M206110 proved to be effective
at attenuating DSS-induced colitis. Administration of







2012 [45] BALB/c mice A mutant of L. lactis In vivo, DSS-induced colitis
L. lactis could improve the clinical symptoms,
maintain crypt integrity and preserve mucus content.
The number of apoptotic cells, MPO activity and




2016 [52] Male C57 mice B. subtilis In vivo, DSS-induced colitis
B. subtilis treatment ameliorated gut inflammation
and dysbiosis -
Hong et al., 2010 [46] Male ICR mice L. brevis HY7401, L. sp. HY7801and B. longum HY8004 In vivo, DSS-induced colitis
Increased levels of acetate, butyrate, and glutamine
and decreased levels of trimethylamine -
Garrido-Mesa et al.,
2011 [47] C57BL/6J mice E. coli Nissle 1917 In vivo, DSS-induced colitis
E. coli Nissle 1917 administration exerted intestinal
anti-inflammatory effect and attenuated the
reactivation of the colitis
-
Zheng et al.,
2016 [48] Female C57BL/6 mice
L. rhamnosus NutRes 1 and
B. breve NutRes 204 In vivo, DSS-induced colitis
An increased expression of inflammation markers




2015 [49] Female C57BL/6 mice
Capsules with bifidobacteria,
lactobacilli, and S. thermophilus In vivo, DSS-induced colitis
Probiotic mixture attenuated the disease activity
index score and colon inflammation and also
inflammation markers
-
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Table 2. Cont.




Dai et al., 2013 [50] Male Wistar rats Capsules with bifidobacteria,lactobacilli, and S. thermophilus In vivo, DSS-induced colitis
The probiotic mixture have anti-inflammatory
properties reducing the disease activity index, MPO
activity, inflammation biomarkers, and also increasing
of IL-10 expression
-
Salim et al., 2013 [51] Adult male 129/SvEvmice
Capsules with bifidobacteria,
lactobacilli, and S. thermophilus
In vivo, acute intestinal
ischemia/reperfusion injury
Levels of active NF-κB were significantly higher in the
control group, corroborating with the inflammation of
the tissue, which was attenuated by probiotic
administration
-
Satish Kumar et al.,
2015 [53] Wistar female rats L. plantarum 21 In vivo, TNBS-induced colitis
Treatment with L. plantarum 21 for 14 days after
induction of colitis decreased TBARS, NO, IL-1β and
TNF-α and increased glutathione concentration and
IL-10 expression
-
Yang et al., 2013 [54] Sprague-Dawley Rats Lactobacilli and bifidobacteria In vivo, TNBS-induced colitis TLR4 and TNF-α expression were reducedwith probiotics -
Eeckhaut et al.,
2013 [55] Male Wistar rats B. pullicaecorum In vivo, TNBS-induced colitis
B. pullicaecorum administration resulted in a decreased
intestinal MPO, TNF-α and IL-12 levels -
Schmitz et al., 2015
[56,57] Dogs E. faecium NCIMB 10415 E1707 Chronic enteropathies
There was no difference between groups or
treatments regarding clinical efficacy, histology scores -
Sun et al., 2015 [58] BALB/c mice L. delbrueckii Intestinal malfunction inducedby Lincomycin hydrochloride
L. delbrueckii administration increased secretory










L. plantarum LS/07 CCM7766 and its combination
with inulin abolished inflammatory process in the
jejunal mucosa
-
Ogita et al., 2015 [60] DQ8 transgenic mice
L. rhamnosus OLL2838, B. infantis
ATCC 15697, and S. thermophilus
Sfi 39
In vivo, model of
gluten-specific enteropathy
Probiotic administration enhanced total glutathione
and glutathione S-transferase activity, whereas
caspase-3 activity was reduced
-
Wu et al., 2015 [61] Female C57BL/6 mice L. rhamnosus GG and L. plantarum In vivo, vitamin D receptorknockout mice
Probiotic treatment conferred physiological and
histologic protection from colitis -
AE, adverse event; DSS, dextran sulfate sodium; IL, interleukin; MPO, myeloperoxidase; NF-κB, nuclear factor kappa-B; NO nitric oxide; TBARS, thiobarbituric acid reactive substances;
TNF-α, tumor factor necrosis alpha; TNBS, 2,4,6 trinitrobenzenesulfonic acid; TLR, toll-like receptor.
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3.2.2. Humans
Ulcerative Colitis
UC is a chronic IBD of unknown etiology that is characterized by acute exacerbations of intestinal
complications, followed by remissions. Additionally, one of the main hypotheses is that UC is caused
by an excessive immune response to endogenous bacteria in genetically predisposed individuals.
Therefore, the manipulation of the mucosal microbiota to reduce the inflammatory potential of
colonizing bacteria is an attractive therapy for UC. Recently, probiotic therapy has been demonstrated
to be potentially effective and safe in patients with UC. Tamaki et al., 2016 investigated the efficacy
and safety of probiotic treatment with B. longum 536, which is a probiotic isolated in 1969 from the
feces of a breast-fed infant, in Japanese patients with active UC using an RCT [62]. The probiotic
improved clinical symptoms, such as the UC disease activity index and Rachmilewitz endoscopic
index, in patients with mild to moderately active UC, but further studies are needed to clarify the
efficacy and safety of B. longum 536 for UC [62].
A single-center, randomized, double-blind, placebo-controlled study was conducted to examine
whether 12 months of probiotic therapy, including a mixture of the strains Streptococcus faecalis T-110,
Clostridium butyricum TO-A, and Bacillus mesentericus TO-A, was useful for preventing the relapse
of UC in patients who were already in remission. The relapse rates in the probiotic therapy group
increased significantly at three and nine months. However, no differences were noted at 12 months.
Moreover, in a cluster analysis of fecal microbiota, which is a molecular technique that compares the
diversity and colony structure of microbial complexes, seven patients belonged to cluster I; 32 to cluster
II, which is the “appropriate intestinal microbiota”; and seven to cluster III. Therefore, probiotics may
be effective for UC, especially in cluster I patients [63].
With regards to UC, a RCT was conducted to assess the clinical efficacy of profermin, a food with
fermented oats containing L. plantarum 299v and other ingredients such as barley malt and lecithin, in
relapsing UC. The patients with a mild-to-moderate flare-up of UC, which was defined as a Simple
Clinical Colitis Activity Index (SCCAI) score ≥5 and ≤1, showed a significant decrease in the SCCAI
score after probiotic supplementation. Thus, L. plantarum 299v administration was safe, well tolerated,
and palatable, and induced a clinically significant reduction in the SCCAI score compared with a
placebo in patients with mild-to-moderate flare-up of UC [64].
A recent case report of bacteremia was caused by L. rhamnosus GG in an adult patient affected
by severe active UC under treatment with corticosteroids and mesalazine. Lactobacillus species are
ubiquitous Gram-positive commensals of the normal human microbiota, but their role as opportunistic
pathogens is emerging. The case of bacteremia was apparently associated with the translocation of
bacteria and fungi from the intestinal lumen to the blood. Thus, Candida infection was likely promoted
by previous extensive antibiotic use, whereas L. rhamnosus GG infection was most likely associated
with the probiotic strain administered to the patient and possibly favored by the use of vancomycin,
to which the strain was resistant. Notably, this observation based on pending conclusive evidence
suggests that the use of probiotics should be considered with caution in cases of active severe IBD with
mucosal disruption [65].
UC is also associated with fecal dysbiosis, and different human and animal studies suggest
that the gastrointestinal microbiome may trigger the intestinal immune response. Fecal microbial
transplantation (FMT) may be a therapeutic option. However, a clinical report published by
Suskind et al. (2015) described that single-dose FMT via a nasogastric tube was well tolerated in four
patients with UC, but no clinical benefit was demonstrated [66]. Recently, Paramsothy et al., 2017 have
reported that intensive-dosing, multidonor FMT induces clinical remission and endoscopic improvement
in active UC and is associated with distinct microbial changes that relate to the outcome [67].
Conversely, a 2014 case report by Brace et al. indicated that FMT may be a promising therapy for
Clostridium difficile infection (CDI) in patients with IBD, because colonization with toxigenic C. difficile
is significantly higher in IBD patients compared with the general population [68]. Thus, an IBD
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patient with two CDIs was treated 18 months apart, and each infection was successfully treated
with FMT with no IBD flares or complications. Only this study described sequential FMT from a
single donor for an IBD patient with CDI recurrences. Microbiota composition analysis indicated
that the patient’s pre-transplant samples exhibited reduced diversity, with deficiencies in the usually
dominant populations of Firmicutes and Bacteroidetes. This microbiota pattern is consistent with
microbial analyses of non-IBD patients during CDI, thus supporting the theory that predominating
Firmicutes and Bacteroidetes groups may confer colonization resistance against C. difficile. The authors
described only one patient-donor set, which is the main limitation of this study; therefore, further
studies are needed to approach the vulnerability profile of patients at risk of relapse [68].
A case report described by Vahabnezhad et al., 2013 reported that probiotic strains of Lactobacillus,
L. rhamnosus GG, caused bacteremia in a 17-year-old boy with UC managed with systemic
corticosteroids and infliximab, which is a tumor necrosis factor-α antagonist [69]. L. rhamnosus GG
was assessed via blood culture on day 2, but the subsequent blood cultures on day 3 and 5 were
negative. The patient was treated with antibiotics for five days and defervesced by day eight of his
illness. The authors hypothesize that the immunosuppressive effects from systemic corticosteroids
and infliximab may have also predisposed the patient to a higher risk of infection.
The risk of infection due to lactobacilli and bifidobacteria is extremely rare and represents
0.05–0.4% of cases of infective endocarditis and bacteremia. Meanwhile, historically, Lactobacillus spp.
found in food has been considered to be insignificant and they are often regarded as contaminants
when isolated from patient samples. Therefore, although probiotics can offer potential benefits in
certain healthy conditions, their risks and benefits should still be carefully assessed in patients with
some complications, especially when the patients might be immunocompromised [69,70].
Crohn’s Disease
CD is a systemic disorder in which the development of host genetic susceptibility represents
an important etiological factor. Multiple studies have observed differences in the microbiotas
of individuals with CD, with a reduction in anti-inflammatory bacteria and an increase in
pro-inflammatory bacteria compared with the microbiotas of healthy subjects. In this sense, different
studies have focused on reporting the effect of some strains in CD in recent years. Petersen et al., 2014
investigated the effects of E. coli, which is a member of the phylogenetic group B2, and its association
with both CD and UC [71]. Interestingly, the probiotic E. coli Nissle, 1917 has an equivalent effect
to mesalazine in preventing disease flares in UC patients. Moreover, antibiotics seem to have some
effect in the treatment of IBD patients. Thus, these authors designed a study to investigate whether
ciprofloxacin for one week, followed by therapy with E. coli Nissle, 1917 for seven weeks, or either of
these treatments alone, influence the remission rate among UC patients. However, no benefit in the use
of E. coli Nissle 1917 as an add-on treatment to conventional therapies for active UC was noted [71].
Fedorak et al., 2015 investigated the effects of capsules with bifidobacteria, lactobacilli, and
S. thermophilus DSM24731 in preventing the recurrence of CD after surgery [72]. The recurrence after
intestinal resection in CD is quite common. Thus, in this study, within 30 days of ileocolonic resection
and re-anastomosis, patients with CD were randomly assigned to groups administered capsules versus
a placebo. Although there were no differences in the endoscopic recurrence rates at day 90 between
patients who received the probiotics strains, the mucosal levels of inflammatory cytokines, such as IL-8
and IL-1β, were lower among patients who received the probiotics. However, the authors concluded
that additional studies are necessary to confirm the effect of the probiotic mixture in the prevention of
postoperative recurrence [72].
Hevia et al., 2014 explored the levels of antibodies (IgG and IgA) raised against extracellular
proteins produced by LAB and its association with IBD [73]. The presence of serum antibodies, such as
IgG and IgA produced by food bacteria from the genera Bifidobacterium and Lactobacillus, which are
used as serum biomarkers of CD or UC, were determined by western blot and ELISA in sera collections
from healthy individuals, CD patients, and UC patients. The levels of IgA antibodies against a cell-wall
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hydrolase from L. casei subsp. rhamnosus GG (CWH) were significantly higher in the IBD group and
appeared to have different immune responses to food bacteria. Specifically, IgA antibodies developed
against an extracellular protein of L. casei are associated with IBD. Therefore, these results suggest that
anti-CWH IgA levels have a potential use for the early detection of CD and UC. However, studies with
larger sample sizes are necessary. In addition, the identification of other extracellular protein targets
present in food and probiotic bacteria is needed [73].
Ahmed et al., 2013 performed a pilot study in patients with colitis, randomized to either receive
a synbiotics for a month and then “crossed over” to receive a placebo or alternatively to receive the
placebo first followed by the symbiotic [74]. The main results showed that there were no differences in
colonic microbiota between patients with CD or UC, and the spectrum bacteria were not altered by
synbiotic administration [74].
Pouchitis is a nonspecific inflammation of the pouch that is present in UC patients and remains
the most common post-operative long-term complication. Inflammation of the pouch is characterized
by increased stool frequency, rectal bleeding, abdominal cramping, urgency, and fever, and the
pathogenesis of pouchitis is still poorly understood. However, there is evidence that implicates
the gut microbiota, suggesting that probiotics could reduce the risk of the recurrence of pouchitis,
but the mechanisms are not fully understood. Persborn et al., 2013 reported that treatment with
probiotic mixture for eight weeks after antibiotics restored the increased permeation to E. coli K12 in
16 patients with chronic pouchitis [75]. Thirteen individuals served as a control. This finding could be
an important factor for the prevention of recurrence during maintenance treatment with probiotics for
this inflammatory status [75].
The bacteria B. infantis 35,624 exerts beneficial immunoregulatory effects by mimicking
commensal-immune interactions. In an RCT, B. infantis 35,624 was used to assess the impact of
oral administration for six to eight weeks on inflammatory biomarker and plasma cytokine levels in
patients with UC, chronic fatigue syndrome, and psoriasis. B. infantis 35,624 reduced plasma CRP levels
in all three inflammatory disorders compared with the placebo. Interestingly, plasma IL-6 was reduced
in UC patients and chronic fatigue syndrome. Furthermore, in healthy subjects, LPS-stimulated TNF-α
and IL-6 secretion by peripheral blood mononuclear cells was significantly reduced in the B. infantis
35,624-treated groups compared with the placebo following eight weeks of feeding. These findings
demonstrate the reduction of systemic pro-inflammatory biomarkers by B. infantis 35,624 and the
immunomodulatory effects of the microbiota in humans [76].
In humans, an RCT was described by Bourreille et al., 2013, which was a prospective study
with 165 patients with CD who achieved remission after treatment with steroids or salicylates [77].
The patients were randomly assigned to groups that received S. boulardii or placebo for 52 weeks.
No differences in the median time to relapse were noted between the groups. Thus, although the
probiotic yeast S. boulardii effects were positive in animals, it does not appear to have any beneficial
effects for patients with CD in remission after steroid or salicylate therapies [77].
In summary, the supplementation of selected probiotics appears to be potentially well tolerated,
effective, and safe in patients with IBD, both CD and UC. Indeed, probiotics such as B. longum
536 improved clinical symptoms in patients with mild to moderately active UC. Although it has been
proposed that probiotics can provide benefits in certain conditions, such as healthy individuals or
individuals with obesity or metabolic syndrome, the risks and benefits should be carefully assessed
before initiating any therapy in patients with IBD. Table 3 summarizes the studies of probiotics and
synbiotics in humans.
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Table 3. Summary of probiotic effects on IBD in human studies.
Reference Subjects Probiotic Strains/Treatment Time Main Outcome Adverse Event/Adverse Effects
Tamaki et al.,
2016 [62] 56 with mild to moderate UC B. longum 536 8 weeks
Probiotics administration improved clinical symptoms in
the patients with mild to moderately active UC -
Yoshimatsu et al.,
2015 [63]
60 outpatients with UC in
remission
S. faecalis, C. butyricum and
B. mesentericus 12 months
Probiotic may be effective for maintaining clinical
remission in patients with UC -
Krag et al.,
2013 [64]
74 patients with a
mild-to-moderate UC L. plantarum 299v 8 weeks
Probiotic supplementation was safe, well tolerated,
palatable, and able to reduce disease index scores in
patients with mild-to-moderate UC
-
Petersen et al.,
2014 [71] 100 patients with UC E. coli Nissle 1917 7 weeks
There is no benefit in the use of E. coli Nissle as an add-on
treatment to conventional therapies for active UC -
Fedorak et al.,
2015 [72]
119 patients with CD (within
30 days of ileocolonic
resection and re-anastomosis
Capsules with bifidobacteria,
lactobacilli, and S. thermophilus 90 days
There were no differences in endoscopic recurrence, but
mucosal levels of inflammatory cytokines such as IL-8,





50 healthy individuals, 37 CD
patients and 15 UC patients L. casei subsp. rhamnosus GG 90 days
Levels of IgA antibodies developed against a cell-wall
hydrolase from L. casei subsp. rhamnosus GG were




8 patients with CD and
8 patients with UC
L. acidophilus LA-5, L. delbrueckii
subsp. bulgaricus LBY-27, B. animalis
subsp. lactis BB-12, S. thermophilus
STY-31 and 15 g oligofructose
1 month
There were no differences in colonic microbiota between
patients with CD or UC and the spectrum a bacterium




16 patients with chronic
pouchitis and 13 individuals
as a control
L. acidophilus Ecologic 825: B. bifidum
(W23), B. lactis (W51), B. lactis (W52),
L. acidophilus (W22), L. casei (W56),
L. paracasei (W20), L. plantarum (W62),
L. salivarius (W24) and L. lactis (W19)
8 weeks Probiotics restored the mucosal barrier to E. coli inpatients with pouchitis -
Groeger et al.,
2013 [76]




B. infantis 35,624 6–8 weeks
Probiotics administration reduced the systemic




2013 [77] 165 patients with CD S. boulardii 52 weeks
Probiotics were well tolerated but it did not show any
effect. Twenty-one AEs occurred during the treatment,
these affected 17 patients, 9 in the S. boulardii group and
8 in placebo group
Twenty-one AEs occurred
during the treatment,
these affected 17 patients,
9 in the S. boulardii group
and 8 in placebo group
AE, adverse event; CD, Crohn’s disease; UC, ulcerative colitis.
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4. Further Research and Directions
For a selected number of probiotics and synbiotics, the intestinal anti-inflammatory effects have
been documented using in vitro and experimental approaches, as well as human studies. However,
the appropriate doses and time of treatment have not been defined, and for a majority of them,
the molecular mechanism of action has not been ascertained. Further research should evaluate the
most appropriate doses and time of treatment for each probiotic and synbiotic in terms of efficacy
in the control of specific chronic inflammatory diseases, and how they contribute to ameliorate
the symptoms of the disease as related to the decrease of intestinal and systemic biomarkers of
inflammation. In addition, the interactions of particular probiotics with cell receptors and how cell
signaling cascades are affected, as well as how the expression of intestinal host genes involved in
the immune and inflammatory responses are modulated, are key aspects to understand the action
of probiotics. Moreover, the next generation sequence systems should contribute to knowledge on
the individual intestinal ecology of patients affected with inflammatory intestinal diseases and the
commensal and probiotics strains that actually have a key role in the control of biodiversity in the
intestine. This should include the sequencing not only of the bacterial metagenomes, but also the
intestinal viromes, thus envisaging the potentially efficient and safe fecal transplantation of healthy
subjects to intestinal chronic inflamed patients.
Finally, Figure 1 represents the summary of anti-inflammatory effects of probiotics and synbiotics
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59. Štofilová, J.; Szabadosová, V.; Hrčková, G.; Salaj, R.; Bertková, I.; Hijová, E.; Strojný, L.; Bomba, A.
Co-administration of a probiotic strain Lactobacillus plantarum LS/07 CCM7766 with prebiotic inulin alleviates
the intestinal inflammation in rats exposed to N,N-dimethylhydrazine. Int. Immunopharmacol. 2015, 24,
361–368. [CrossRef] [PubMed]
60. Ogita, T.; Bergamo, P.; Maurano, F.; D′Arienzo, R.; Mazzarella, G.; Bozzella, G.; Luongo, D.; Sashihara, T.;
Suzuki, T.; Tanabe, S.; et al. Modulatory activity of Lactobacillus rhamnosus OLL2838 in a mouse model of
intestinal immunopathology. Immunobiology 2015, 220, 701–710. [CrossRef] [PubMed]
61. Wu, S.; Yoon, S.; Zhang, Y.G.; Lu, R.; Xia, Y.; Wan, J.; Petrof, E.O.; Claud, E.C.; Chen, D.; Sun, J. Vitamin D
receptor pathway is required for probiotic protection in colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2015,
309, 341–349. [CrossRef] [PubMed]
62. Tamaki, H.; Nakase, H.; Inoue, S.; Kawanami, C.; Itani, T.; Ohana, M.; Kusaka, T.; Uose, S.; Hisatsune, H.;
Tojo, M.; et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in
active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig. Endosc.
2016, 28, 67–74. [CrossRef] [PubMed]
63. Yoshimatsu, Y.; Yamada, A.; Furukawa, R.; Sono, K.; Osamura, A.; Nakamura, K.; Aoki, H.; Tsuda, Y.;
Hosoe, N.; Takada, N.; et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with
inactive ulcerative colitis. World J. Gastroenterol. 2015, 21, 5985–5994. [PubMed]
64. Krag, A.; Munkholm, P.; Israelsen, H.; von Ryberg, B.; Andersen, K.K.; Bendtsen, F. Profermin is efficacious in
patients with active ulcerative colitis-a randomized controlled trial. Inflamm. Bowel Dis. 2013, 19, 2584–2592.
[CrossRef] [PubMed]
65. Meini, S.; Laureano, R.; Fani, L.; Tascini, C.; Galano, A.; Antonelli, A.; Rossolini, G.M. Breakthrough
Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active
ulcerative colitis: case report and review of the literature. Infection 2015, 43, 777–781. [CrossRef] [PubMed]
66. Suskind, D.L.; Namita Singh, N.; Nielson, H.; Wahbeh, G. Fecal microbial transplant via nasogastric tube for
active pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 2015, 60, 27–29. [CrossRef] [PubMed]
67. Paramsothy, S.; Kamm, M.A.; Kaakoush, N.O.; Walsh, A.J.; van den Bogaerde, J.; Samuel, D.; Leong, R.W.;
Connor, S.; Ng, W.; Paramsothy, R.; et al. Multidonor intensive faecal microbiota transplantation for active
ulcerative colitis: A randomised placebo-controlled trial. Lancet 2017, 389, 1218–1228. [CrossRef]
68. Brace, C.; Gloor, G.B.; Ropeleski, M.; Allen-Verco, E.; Petrof, E.O. Microbial composition analysis
of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota
transplantations. J. Crohns Colitis 2014, 8, 1133–1137. [CrossRef] [PubMed]
69. Vahabnezhad, E.; Mochon, A.B.; Wozniak, L.Y.; Ziring, D.A. Lactobacillus bacteremia associated with probiotic
use in a pediatric patient with ulcerative colitis. Clin. Gastroenterol. 2013, 47, 437–439. [CrossRef] [PubMed]
70. Gouriet, F.; Million, M.; Henri, M.; Fournier, P.E.; Raoult, D. Lactobacillus rhamnosus bacteremia: An emerging
clinical entity. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 2469–2480. [CrossRef] [PubMed]
71. Petersen, A.M.; Mirsepasi, H.; Halkjær, S.I.; Mortensen, E.M.; Nordgaard-Lassen, I.; Krogfelt, K.A.
Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind
randomized placebo controlled clinical trial. J. Crohns Colitis 2014, 8, 1498–1505. [CrossRef] [PubMed]
72. Fedorak, R.N.; Feagan, B.G.; Hotte, N.; Leddin, D.; Dieleman, L.A.; Petrunia, D.M.; Enns, R.; Bitton, A.;
Chiba, N.; Paré, P. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence
after surgery for crohn’s disease. Clin. Gastroenterol. Hepatol. 2015, 13, 928–935. [PubMed]
Nutrients 2017, 9, 555 19 of 19
73. Hevia, A.; López, P.; Suárez, A.; Jacquot, C.; Urdaci, M.C.; Margolles, A.; Sánchez, B. Association of levels of
antibodies from patients with inflammatory bowel disease with extracellular proteins of food and probiotic
bacteria. Biomed. Res. Int. 2014, 2014, 351204. [CrossRef] [PubMed]
74. Ahmed, J.; Reddy, B.S.; Mølbak, L.; Leser, T.D.; MacFie, J. Impact of probiotics on colonic microflora in
patients with colitis: A prospective double blind randomised crossover study. Int. J. Surg. 2013, 11, 1131–1136.
[CrossRef] [PubMed]
75. Persborn, M.; Gerritsen, J.; Wallon, C.; Carlsson, A.; Akkermans, L.M.A.; Söderholm, J.D. The effects of
probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe
pouchitis in patients with ulcerative colitis. Aliment Pharmacol. Ther. 2013, 38, 772–783. [CrossRef] [PubMed]
76. Groeger, D.; O’Mahony, L.; Murphy, E.F.; Bourke, J.F.; Dinan, T.G.; Kiely, B.; Shanahan, F.; Quigley, E.M.M.
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 2013, 4,
325–339. [CrossRef] [PubMed]
77. Bourreille, A.; Cadiot, G.; Le Dreau, G.; Laharie, D.; Beaugerie, L.; Dupas, J.L.; Marteau, P.; Rampal, P.;
Moyse, D.; Saleh, A. Saccharomyces boulardii does not prevent relapse of Crohn′s disease. Clin. Gastroenterol. Hepatol.
2013, 11, 982–987. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
